Alteration in insulin receptor expression accompanying differentiation of HL-60 leukemia cells.
Differentiation of leukemic cells in vitro is characterized by the sequential appearance of morphological, functional, and biochemical markers of maturation. The interaction of insulin with its receptor may be a regulator of growth and differentiation of leukemic cells. Human promyelocytic leukemia cells (HL-60) demonstrate specific reversible insulin binding consistent with properties of human insulin receptor. HL-60 cells treated with 500 microM N6,O2-dibutyryl adenosine 3',5'-cyclic monophosphate, 1 microM 1 alpha, 25-dihydroxyvitamin D3, or 41 nM phorbol-12-myristate-13-acetate expressed monocytic markers of differentiation and an increase in insulin receptor expression. The change in insulin receptor expression with 1 microM 1 alpha, 25-dihydroxyvitamin D3 and N6,O2-dibutyryl adenosine 3',5'-cyclic monophosphate induction was further characterized by Scatchard analysis. High affinity binding (Kd) constant was not altered, and the change in binding was attributed to receptor number. Commitment to increased insulin receptor expression was demonstrated after 1-h exposure to 1 microM 1 alpha, 25-dihydroxyvitamin D3. Agents which induced granulocytic differentiation, such as 160 mM dimethyl sulfoxide and 100 nM retinoic acid, significantly decreased insulin receptor expression compared to monocytic inducing agents. This difference in insulin receptor expression correlated with binding characteristics in normal human peripheral granulocyte and monocytes. The HL-60 cell line offers a model for the study of the molecular events which lead to the contrasting insulin receptor expression during myeloid and monocytoid hematopoiesis.
D003994:Bucladesine / Q000494:pharmacology; D002454:Cell Differentiation; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D015232:Dinoprostone; D006098:Granulocytes / Q000378:metabolism; D006801:Humans; D007942:Leukemia, Experimental / Q000378:metabolism* / Q000473:pathology; D009000:Monocytes / Q000378:metabolism; D009283:Naphthol AS D Esterase / Q000378:metabolism; D009580:Nitroblue Tetrazolium / Q000378:metabolism; D011458:Prostaglandins E / Q000494:pharmacology; D011972:Receptor, Insulin / Q000378:metabolism*; D013806:Theophylline / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology; D014807:Vitamin D / Q000494:pharmacology
D011458:Prostaglandins E; D014807:Vitamin D; D009580:Nitroblue Tetrazolium; D014212:Tretinoin; D003994:Bucladesine; D013806:Theophylline; D011972:Receptor, Insulin; D009283:Naphthol AS D Esterase; D015232:Dinoprostone; D004121:Dimethyl Sulfoxide